A novel second-generation approach to achieve a safe, durable, and stable transgene expression to overcome the challenges of factor VIII replacement therapies
Technology Development Board supports commercialisation of Metal Injection Molding of implants
The amalgamation will integrate business operations and provide impetus to the existing portfolio of Alembic
John Shaw, who is a Glasgow University graduate, along with his wife Kiran Mazumdar-Shaw had gifted US $ 7.5 million to the university in July 2019
New collaboration will help customers reach sustainability goals for high-performance Udel PSU polymers in demanding applications.
Dupixent peak sales ambition raised to more than €13 billion
Tardive dyskinesia (TD) is a movement disorder that is characterized by uncontrollable, abnormal and repetitive movements of the face, torso and/or other body parts, which may be disruptive and negatively impact patients
As a partner with IRIA, the company had a significant booth presence on-ground during the conference.
Novel tool bypasses plasmid-based expression to increase stability and significantly reduce development time for a variety of synthetic biotechnology products
AbbVie to present 30 abstracts demonstrating its leadership in neuroscience, including continued migraine treatment research across the spectrum of the disease, commitment to patients with advanced Parkinson's disease, and new studies in spasticity and cervical dystonia
Subscribe To Our Newsletter & Stay Updated
